A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study

References

• Altman R. D. Criteria for classification of clinical osteoarthritis. J. Rheum. 1991; 18(27)10–121. Altman R. D. Criteria for classification of clinical osteoarthritis. J. Rheum. 1991; 18(27)10–12
   Google Scholar
• Auer I. O. Advances and perspectives of prophylaxis and therapy of gastrointestinal side effects of drug therapy with non-steroidal antiinflammatory drugs. Aktuel Reumatol. 1986; 11: 210–2162. Auer I. O. Advances and perspectives of prophylaxis and therapy of gastrointestinal side effects of drug therapy with non-steroidal antiinflammatory drugs. Aktuel Reumatol. 1986; 11: 210–216
   Web of Science ®Google Scholar
• Coles L. M., Fries J. F., Kraines R. G., Roth S. H. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. Am. J. Med. 1983; 74: 820–8283. Coles L. M., Fries J. F., Kraines R. G., Roth S. H. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. Am. J. Med. 1983; 74: 820–828
   PubMed Web of Science ®Google Scholar
• De La Torre G. Efficacy and tolerance of piroxicam suppositories in the treatment of osteoarthritis. Curr. Ther. Rex Clin. Exp. 1990; 48: 434–4394. De La Torre G. Efficacy and tolerance of piroxicam suppositories in the treatment of osteoarthritis. Curr. Ther. Rex Clin. Exp. 1990; 48: 434–439
   Web of Science ®Google Scholar
• Distel M., Mueller C., Bluhmki E., Fries J. Global analysis of safety of a new NSAID, Meloxicam, Submitted for publication5. Distel M., Mueller C., Bluhmki E., Fries J. Global analysis of safety of a new NSAID, Meloxicam, Submitted for publication
   Google Scholar
• Engelhardt G., Homma D., Schlegel K., Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Rex 1995; 44(10)423–4336. Engelhardt G., Homma D., Schlegel K., Schnitzler Chr. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Rex 1995; 44(10)423–433
   PubMed Web of Science ®Google Scholar
• Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at the 9th International conference on prostaglandins and related compounds, FlorenceItaly, 6–10 June, 1994, P827. Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at the 9th International conference on prostaglandins and related compounds, FlorenceItaly, 6–10 June, 1994, P82
   Google Scholar
• Goei Thé H., Lund B., Distel M., Bluhmki E. A double blind randomised trial comparing meloxicam with diclofenac in osteoarthritis (OA). Rheumutol. Eur. 1995; 24, Suppl. 3, Abstract E518. Goei Thé H., Lund B., Distel M., Bluhmki E. A double blind randomised trial comparing meloxicam with diclofenac in osteoarthritis (OA). Rheumutol. Eur. 1995; 24, Suppl. 3, Abstract E51
   Google Scholar
• Hatori M., Sukurai M., Kokubun S., Rijal K. Piroxicam suppositories in the treatment of osteoarthritis of the knee. Clin. Ther. 1990; 12: 227–2299. Hatori M., Sukurai M., Kokubun S., Rijal K. Piroxicam suppositories in the treatment of osteoarthritis of the knee. Clin. Ther. 1990; 12: 227–229
   PubMed Web of Science ®Google Scholar
• Heymen G., Dessain P. Piroxicam suppositories for osteoarthritis and rheumatoid arthritis: an open multicentre study in 116 patients. Eur. J. Rheum. Influm. 1983; 6: 134–13810. Heymen G., Dessain P. Piroxicam suppositories for osteoarthritis and rheumatoid arthritis: an open multicentre study in 116 patients. Eur. J. Rheum. Influm. 1983; 6: 134–138
   PubMed Web of Science ®Google Scholar
• Hosie J., Distel M., Bluhmki E. A six month, double blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis (OA). Rheumatol. Eur. 1995; 24, Suppl. 3, Abstract E5011. Hosie J., Distel M., Bluhmki E. A six month, double blind study comparing meloxicam 15 mg with piroxicam 20 mg in osteoarthritis (OA). Rheumatol. Eur. 1995; 24, Suppl. 3, Abstract E50
   Google Scholar
• Hosie J., Distel M., Bluhmki E. Meloxicam in osteoarthritis: a six-month, doubleblind comparison with diclofenac sodium, Submitted for publication12. Hosie J., Distel M., Bluhmki E. Meloxicam in osteoarthritis: a six-month, doubleblind comparison with diclofenac sodium, Submitted for publication
   Google Scholar
• Karch F. E., Lasagna L. Adverse drug reactions: a critical review. JAMA 1985; 234: 1236–124113. Karch F. E., Lasagna L. Adverse drug reactions: a critical review. JAMA 1985; 234: 1236–1241
   Google Scholar
• Lemmel E. M., Bolten W., Bourgos-Vargas R., Platt P. N., Nissilä M., Sahlberg D., Björneboe O., Baumgartner H., Valat J. P., Franchimont P. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis (RA). Scand. J. Rheumatol. 1994, Suppl. 98, Abstract 11114. Lemmel E. M., Bolten W., Bourgos-Vargas R., Platt P. N., Nissilä M., Sahlberg D., Björneboe O., Baumgartner H., Valat J. P., Franchimont P. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis (RA). Scand. J. Rheumatol. 1994, Suppl. 98, Abstract 111
   Web of Science ®Google Scholar
• Lindén B., Distel M., Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip, Submitted for publication15. Lindén B., Distel M., Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip, Submitted for publication
   Google Scholar
• Lund B., Distel M., Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam patients with osteoarthritis (OA) of the knee. Scand. J. Rheumatol. 1994, Suppl. 98, Abstract 11716. Lund B., Distel M., Bluhmki E. A double-blind placebo controlled study of three different doses of meloxicam patients with osteoarthritis (OA) of the knee. Scand. J. Rheumatol. 1994, Suppl. 98, Abstract 117
   Google Scholar
• Macca F., Milani L., Dal Folla M., Corebetta L., Zeni G., Zuin R. Attività terapeutica del piroxicam per via rettale nelle malattie reumatiche. Minerva Medica 1984; 75: 811–81917. Macca F., Milani L., Dal Folla M., Corebetta L., Zeni G., Zuin R. Attività terapeutica del piroxicam per via rettale nelle malattie reumatiche. Minerva Medica 1984; 75: 811–819
   PubMedGoogle Scholar
• Türck D., Busch U., Heinzel G., Narjes H. The basic clinical pharmaco-kinetics of meloxicam, a new NSAID. Rheurnutol. Eur. 1995; 24, Suppl. 3, Abstract D1618. Türck D., Busch U., Heinzel G., Narjes H. The basic clinical pharmaco-kinetics of meloxicam, a new NSAID. Rheurnutol. Eur. 1995; 24, Suppl. 3, Abstract D16
   Google Scholar
• Vane J. R., Botting R. M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Rex 1995; 44: 1–1019. Vane J. R., Botting R. M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Rex 1995; 44: 1–10
   PubMed Web of Science ®Google Scholar
• Wojtulewski J. A., Schattenkirchner M., BarcelÓ P., Le Loet X., North N., Bluhmki E., Distel M. Six month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis, Submitted for publication20. Wojtulewski J. A., Schattenkirchner M., BarcelÓ P., Le Loet X., North N., Bluhmki E., Distel M. Six month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis, Submitted for publication
   Google Scholar